Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $28.8500 (2.3%) ($27.8000 - $29.8000) on Mon. Nov. 9, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.68% (three month average) | RSI | 49 | Latest Price | $28.8500(2.3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.4% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.84% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-2%) EDOC(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.84% (StdDev 3.68%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $28.32(1.87%) | 10 Day Moving Average | $27.2(6.07%) | 20 Day Moving Average | $27.84(3.63%) | To recent high | -7.3% | To recent low | 56.1% | Market Cap | $3.654b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |